Authors:
Gino K. In1, Jun Yin2, Phillip Walker2, Justin Moser3, Joanne Xiu2, Kelsey Poorman2, Geoffrey Thomas Gibney4, Matthew Oberley2, Thuy Phung5, Leonel Hernandez-Aya6, Jose Lustzky6, Wolfgang Michael Korn2, Michael Atkins4
Background
Acral lentiginous melanoma (ALM) is a rare melanoma subtype found on the palms, soles and nailbeds. ALM is poorly responsive to immune checkpoint blockade and outcomes are poor for patients with advanced or metastatic disease. As such, novel treatment approaches are needed.
Download Publication
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |